Madrigal Pharmaceuticals, Inc. (MDGL)
- Previous Close
291.82 - Open
292.44 - Bid 289.13 x 200
- Ask 292.91 x 300
- Day's Range
288.00 - 294.40 - 52 Week Range
200.63 - 377.46 - Volume
289,517 - Avg. Volume
372,636 - Market Cap (intraday)
6.46B - Beta (5Y Monthly) -0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-17.84 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
421.93
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
www.madrigalpharma.comRecent News: MDGL
View More
Performance Overview: MDGL
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGL
View MoreValuation Measures
Market Cap
6.46B
Enterprise Value
5.74B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.98
Price/Book (mrq)
9.09
Enterprise Value/Revenue
18.08
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-123.38%
Return on Assets (ttm)
-25.56%
Return on Equity (ttm)
-50.16%
Revenue (ttm)
317.38M
Net Income Avi to Common (ttm)
-391.59M
Diluted EPS (ttm)
-17.84
Balance Sheet and Cash Flow
Total Cash (mrq)
843.07M
Total Debt/Equity (mrq)
16.85%
Levered Free Cash Flow (ttm)
-274.11M